Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;6(10):e755-e766.
doi: 10.1016/S2589-7500(24)00158-4. Epub 2024 Aug 29.

Digital tools in heart failure: addressing unmet needs

Peder L Myhre  1 , Jasper Tromp  2 , Wouter Ouwerkerk  3 , Daniel S W Ting  4 , Kieran F Docherty  5 , C Michael Gibson  6 , Carolyn S P Lam  7
Affiliations
Free article
Review

Digital tools in heart failure: addressing unmet needs

Peder L Myhre et al. Lancet Digit Health. 2024 Oct.
Free article

Erratum in

Abstract

This Series paper provides an overview of digital tools in heart failure care, encompassing screening, early diagnosis, treatment initiation and optimisation, and monitoring, and the implications these tools could have for research. The current medical environment favours the implementation of digital tools in heart failure due to rapid advancements in technology and computing power, unprecedented global connectivity, and the paradigm shift towards digitisation. Despite available effective therapies for heart failure, substantial inadequacies in managing the condition have hindered improvements in patient outcomes, particularly in low-income and middle-income countries. As digital health tools continue to evolve and exert a growing influence on both clinical care and research, establishing clinical frameworks and supportive ecosystems that enable their effective use on a global scale is crucial.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests PLM has received research grants from AstraZeneca and received speaker or consulting honoraria from Amarin, AmGen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Novo Nordisk, Orion Pharma, Pharmacosmos, Vifor, and Us2.ai. JT is supported by the National University of Singapore Start-up Grant, the tier 1 grant from the Ministry of Education, and the Clinician Scientist-Individual Research Grant New Investigator Grant from the National Medical Research Council; has received research support from AstraZeneca and consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche Diagnostics, and Us2.ai; is a patent holder of US-10702247-B2; and has stock options in Us2.ai. KFD has received speaker's honoraria from AstraZeneca, Pharmacosmos, Radcliffe Cardiology, Boehringer Ingelheim, and Fire1; has served on an advisory board for Us2.ai and Bayer and a clinical endpoint committee for Bayer; and has received grant support from Boehringer Ingelheim, Roche Diagnostics, and AstraZeneca (paid to his institution). His employer, the University of Glasgow, has been remunerated by AstraZeneca for work relating to clinical trials. WO has consulted for Us2.ai, is a patent holder of US-10702247-B2, and has stock options in Us2.ai. DTSW is a consultant for AbbVie, Carl Zeiss, Alcon, Novartis, Bayer, Genentech/Roche, and Ocutrx and is a patent holder for EyRIS and for three AI image analysis methodologies or systems. CMG has received funding from CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson Corporation, and the Spontaneous Coronary Artery Dissection Alliance; has provided consulting services to Adaptimmune, Angel/Avertix Medical, AstraZenca, Bayer Corporation, Bioclinica, Boston Clinical Research Institute, Boston Scientific, Bristol Myers Squibb, Caladrius Biosciences, Cardiovascular Research Foundation, CeleCor Therapeutics, CSL Behring, Cytokinetics, Daiichi Sankyo, Duke Clinical Research Institute, Esperion, EXCITE International ($0 received), Fortress Biotech, Gilead Sciences, Inari, Janssen Pharmaceuticals, Johnson & Johnson Corporation, MashUp MD, MD Magazine, Merck, Microport, Micodrop, Miracor, MjHealth, Novartis, NovoNordisk, the Pulmonary Embolism Response Team Consortium, Pfizer, PhaseBio, PHRI, PLxPharma, Revance Therapeutics, the Society for Cardiovascular Angiography & Interventions, Solstic Health/New Amsterdam Pharma, Somahlution/Marizyme, Vectura, Web MD, and Woman As One; holds equity in Absolutys, nference, Dyad Medical, and Fortress Biotech; and has received royalties as a contributor to UpToDate in Cardiovascular Medicine. CPSL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from NovoNordisk and Roche Diagnostics; has served as consultant or on the Advisory Board, Steering Committee, or Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Quidel Corporation, Radcliffe Group, Recardio, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; serves as Cofounder and Non-executive Director of Us2.ai; and has the following patents issued or pending: PCT/SG2016/050217 (for a method for diagnosis and prognosis of chronic heart failure) and US Patent number 10702247 (for an automated clinical workflow that recognises and analyses two-dimensional and Doppler echo images for cardiac measurements and the diagnosis, prediction, and prognosis of heart disease).

References

Publication types